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Background: Currently, sunitinib represents one of the therapeutic strongholds for renal cell carcinoma, but the criteria for
treatment selection are lacking. We assessed the role of vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR)
polymorphisms in the prediction of the clinical outcome in metastatic renal cell carcinoma (mRCC) patients.
Methods: A total of 84 tumour samples from mRCC patients receiving first-line sunitinib were tested for VEGF and VEGFR single-
nucleotide polymorphisms (SNPs). The SNP results were correlated with progression-free survival (PFS) and overall survival (OS).
Results: Median PFS was 8.22 months, although whereas median OS was 32.13 months. The VEGF A rs833061 resulted significant
in PFS (17 vs 4 months; Po0.0001) and OS (38 vs 10 months; Po0.0001). The VEGF A rs699947 was significant for PFS (18 vs 4
months; P¼ 0.0001) and OS (37 vs 16 months; Po0.0001). The VEGF A rs2010963 was significant in PFS (18 vs 8 vs 2 months;
P¼ 0.0001) and OS (31 vs 36 vs 9 months; P¼ 0.0045). The VEGR3 rs6877011 was significant in PFS (12 vs 4 months; P¼ 0.0075) and
OS (36 vs 17 months; P¼ 0.0001). At multivariate analysis, rs833061, rs2010963 and rs68877011 were significant in PFS, and rs833061
and rs68877011 were independent factors in OS.
Conclusions: In our analysis, patients with TT polymorphism of rs833061, CC polymorphism of rs699947, CC polymorphism of
rs2010963 and CG polymorphism of rs6877011 seem to have a worse PFS and OS when receiving first-line sunitinib.
The metastatic renal cell carcinoma (mRCC) therapy scenario has
radically changed in recent years, and currently the therapeutic
strongholds are mostly represented by tyrosine-kinase inhibitors
(TKIs) directed against the vascular endothelial growth factor
(VEGF) signalling pathway. One of these new molecules, approved
for first-line mRCC treatment, is Sunitinib (Motzer et al, 2000;
Lam et al, 2005).
Nevertheless, in spite of interesting activity profile, a large
proportion of patients, ranging from 60 to 70%, are still refractory
to sunitinib and, therefore, they are exposed to potentially relevant
toxicities without any clinical benefit (Motzer et al, 2007, 2009).
Hypoxia and compensatory hyperactivation of angiogenesis are
particularly important in RCC, given the highly vascularised nature
of kidney tumours and the specific association of mutation in VHL,
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a critical regulator of the hypoxic response, with the onset of RCC
(Pantuck et al, 2003).
The VEGF family members are secreted, dimeric glycoproteins
of B40 kDa, consisting of five members, VEGF A, B, C, D and
placental growth factor (PLGF), and binding to specific receptors
(Valtola et al, 1999; Jia et al, 2004; Rini et al, 2008; Stuttfeld and
Ballmer-Hofer, 2009; Zhang et al, 2009).
The VEGF gene is quite complex, with several alternatively
spliced isoforms, and the regulation of expression could differ
between normal and tumour tissue. Interestingly, as all identified
polymorphisms in VEGF are not in the coding region, alternative
mechanisms for their role in gene expression have been proposed.
In fact, although many transcription factors bind to the promoter
regions of VEGF (Pages and Puyssegur, 2005), none occur at the
common polymorphic sites associated with VEGF expression.
Nevertheless, single-nucleotide polymorphisms (SNPs) have been
reported to cause changes in VEGF expression levels (Pander et al,
2007).
The SNPs in the VEGF and VEGF receptor (VEGFR) genes
have been also correlated with tumour neoangiogenesis through
different biological mechanisms.
Numerous SNPs in the promoter, 50-, and 30-untranslated
regions (UTRs) are present in VEGF family genes. The 50- and 30-
UTR contains key regulatory elements that are sensitive to hypoxia
(Minchenko et al, 1994), and contribute to high variability in
VEGF production among tissues (Vaziri et al, 2010). For example,
634 G4C SNP in the 50-UTR of VEGF affects the protein
translation efficiency (Schultz et al, 1999), and 936 C4T SNP in
the 30-UTR influences the circulating plasma concentrations
(Watson et al, 2000) and tumour tissue expression of VEGF
(Renner et al, 2000). However, it is likely that only a small number
of these polymorphisms and haplotypes (linearly linked SNPs)
actually have a functional effect on VEGF translation, whereas
others act as proxies (Koukourakis et al, 2004).
Although a growing body of evidence suggested a possible
correlation between an altered expression of the angiogenetic
pathway and global outcome in colorectal, breast and ovarian
patients treated with antiangiogenetic therapy (Schneider et al,
2008; Schultheis et al, 2008; Hansen et al, 2010; Steffensen et al,
2010; Hansen et al, 2011), data in mRCC are lacking. In a study
performed on blood samples and tumour tissue specimens, Kim
et al (2012) showed a statistically significant difference in patients
with SNP  634 for sunitinib-related hypertension. Another study
published by Garcia-Donas et al (2011) correlated SNPs with
response and toxicities in mRCC patients treated with sunitinib.
The authors showed that polymorphisms in VEGFR3 and
CYP3A5*1 might be able to define a subset of patients with
decreased sunitinib response and tolerability.
Based on these premises we evaluated the potential role of
VEGF and VEGFR polymorphisms to define specific patients
subgroups more likely to benefit from sunitinib therapy in terms of
progression-free survival (PFS) and overall survival (OS).
PATIENTS AND METHODS
Patient selection. A total of 84 patients receiving first-line
sunitinib treatment for histologically proven advanced renal cell
carcinoma were eligible.
Follow-up consisted of physical examination, a complete blood
count, chest radiography and US of the abdomen or CT/MRI
scanning as clinically indicated.
The VEGF and VEGFR genotyping was performed on formalin-
fixed, paraffin-embedded tissue block (B30mg) of renal cell
carcinoma samples in nephrectomy or core biopsies, taken from
the neoplasm periphery.
Paraffin wax was removed with xylene and the samples were
washed twice with 100% ethanol. DNA was isolated from the
deparaffinised tissue using the RecoverAll Total Nucleic Acid
Isolation Kit for FFPE Tissues (Applied Biosystems, Foster City,
CA, USA) according to the manufacturer’s instructions. DNA from
each sample was then eluted in 120 ml of eluting solution.
The SNPs within each gene were selected using the Pupasuite
software (http://pupasuite.bioinfo.cipf.es/index.jsf – version 2.0.0,
bioinfo 2008), the CIPF SNP database (dbSNP) generated by the
National Centre for Biotechnology Information (http://
www.ncbi.nlm.nih.gov/SNP) and by review of the medical
literature, using the following criteria:
(1) The polymorphism had some degree of likelihood to alter the
structure or the expression of the gene in a biologically relevant
manner (i.e., affecting ESE sequences, 30-UTR or promoter
region);
(2) The minor allele frequency was above 10% (with the only
exception of rs2305948, rs6877011 and rs307822); and
(3) The genetic polymorphism was established and well
documented.
Further considerations drove the selection of SNPs for our
study. A correlation between the presence of a specific allele on a
polymorphic site and the expression of the respective protein has
been previously documented for VEGF (Formento et al, 2009;
Chen et al, 2011). The SNPs in regulatory sequences, such as
introns and 50- and 30-UTRs, have been shown to affect mRNA
stability, processing efficiency, isoform expression and localisation.
Moreover, regulatory motif sequences within the 30 UTR of
mRNAs have been shown to affect the stability of the messenger
and/or its translational efficiency. Thus, it can be argued that SNPs
in these sequences may influence VEGF and VEGFR gene
expression. Also on these bases, we selected the SNPs known to
affect VEGF and VEGFR expression and those located in
regulatory sequences, for which a putative role in protein
regulation can be assumed.
Globally, we assumed that selected SNPs had an impact on
protein expression and therefore on biological function.
The selected SNPs were as follows: six polymorphisms in the
VEGFA gene (rs10434, G4A; rs2010963, G4C; rs25648, C4T;
rs3025039, C4T; rs699947, A4C; rs833061, C4T), two in
VEGFC (rs4604006, T4C; rs7664413, C4T), two in VEGFR1
(FLT1) (rs664393, G4A; rs7993418, A4G), four in VEGFR2
(KDR) (rs1870377, A4T; rs2071559, A4G; rs2305948, G4A;
rs7667298, A4G) and three in VEGFR3 (FLT4) (rs307805, A4G;
rs6877011, C4G; rs307822, G4A). Chromosomal locations,
positions and biological effects of investigated VEGF and VEGFR
SNPs have been summarised in Table 1.
The SNP genotyping was performed by TaqMan technology
using SNP genotyping products (Applied Biosystems). The PCR
was performed and genotypes were analysed on the 7300 Real-
Time PCR System (Applied Biosystems) using an ABI Prism 7300
Sequence Detection System software (version 1.3.1, Applied
Biosystems). Each reaction contained 0.2ml of total genomic
DNA. Laboratory personnel blinded to patient status performed
genotyping, and a random 10% of the samples were repeated to
validate genotyping procedures.
All SNPs genotyped had to present an overall call rate ofZ90%
to be included in our analysis; all samples resulted significant
during the analysis and did not need test repetition.
Statistical analysis. Statistical analysis was performed with the
MedCalc software version 10.4.8 (Mariakerke, Belgium) for
Windows.
The association between categorical variables was estimated by
the w2 test.
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Hazard ratios (HRs) for median PFS and OS between groups
were estimated from Cox Regression models. The multivariate
analysis also included adjustments for other variables such as age
(Z65 vso65 years), sex, performance status (Eastern Cooperative
Oncology Group performance score, 0–1 vs 2), haemoglobin at the
time of treatment start (less than lower limit of normal vs normal),
lactate dehydrogenase (41.5 the upper limit of normal vs
normal), corrected calcium (410 vs o10mg dl 1) and nephrect-
omy (yes vs not).
All polymorphisms were examined for deviation from Hardy–
Weinberg equilibrium using the Powermarker v. 3.25 package
(http://statgen.ncsu.edu/powermarker).
Linkage disequilibrium (LD) analysis was also performed using
the Powermarker v. 3.25 package (www.statgen.ncsu.edu/power-
marker). The LD was estimated using r2, with r2¼ 1 indicating
complete LD and r2¼ 0 indicating absent LD.
RESULTS
Hardy–Weinberg equilibrium and LD. The frequencies of the
tested genotypes resulted comparable to those reported in
Caucasians, with no significant deviation from the Hardy–
Weinberg equilibrium.
Linkage disequilibrium was observed for the tumour genotypes
rs833061, rs699947 and rs2010963 of VEGF A (P40.0001),
correlated with either PFS or OS. No LD was observed for
rs6877011 of VEGFR III.
Patient characteristics. For our analysis, 84 patients with
histologically proven mRCC receiving first-line sunitinib were
available: 65 males and 19 females with median age at diagnosis of
64 years (range 47–85) (Table 2).
In all, 73 patients underwent renal surgery, and for 11 patients,
only core biopsies were available. Also, 29 patients were metastatic
at diagnosis, and 21 of these patients were resectable. Of the
patients, 77 had a clear cell renal cell carcinoma histology, and 7
had other types (2 sarcomatoid and 5 undefined). All patients
received sunitinib as first-line treatment with standard schedule (4
weeks on/2 weeks off), and dose reduction was applied in patients
with grade 3 and 4 toxicities, as clinically indicated.
No statistically significant differences were found according to
genotype for major patients characteristics (PS, tumour burden,
and so on).
In the general population, median PFS was 8.22 months,
whereas median OS was 32.13 months.
Genotype analysis. All SNPs genotyped presented an overall call
rate of Z90%.
A total of 60 patients (71%) were found with a CC or CT
genotype of rs833061, whereas 24 patients (29%) had TT genotype.
Median PFS was improved for patients showing the CC/CT
genotype (17 vs 4 months; Po0.0001; Figure 1), as also was
median OS (38 vs 10 months; Po0.0001; Figure 2).
In all, 8 patients (10%) had a CC genotype of rs2010963, 39
patients (46%) had a CG genotype and 37 patients (44%) had a GG
genotype. Progression-free survival proved statistically significant
different among these genotypes with 2 months for CC genotype, 8
months for CG and 18 months for GG (P¼ 0.0001; Figure 3).
Overall survival was significant (9 vs 36 vs 31; P¼ 0.0045).
A total of 60 patients (71%) had an AA or AC genotype for
rs699947 and 24 patients (29%) had a CC genotype. Median PFS
was improved for patients showing the AA/AC genotype (18 vs 4
months; P¼ 0.0001), as also was median OS (37 vs 16 months;
Po0.0001).
An analysis of rs833061, rs2010963 and rs699947 of VEGF A
identifies a population of patients who express these polymorph-
isms in accordance to LD.
In all, 71 patients (85%) expressed a CC genotype of rs6877011
and 13 patients (15%) had a CG genotype. No patients expressed
the GG genotype. For patients showing these polymorphisms, PFS
was of 12 months for CC genotype and 4 months for CG genotype
(P¼ 0.0075; Figure 4) and OS was of 36 months for CC and 17
months for CG (P¼ 0.0001; Figure 5 and Table 3).
Table 1. Chromosomal locations, positions and biological effects of investigated gene SNPs
SNP ID Gene Chr Chr. position Position in the gene/effect Codon exchange aa exchange
rs10434 VEGFA 6 43753212 3’-UTR — —
rs2010963 VEGFA 6 43738350 5’-UTR — —
rs25648 VEGFA 6 43738977 Syn; ESE TCC TCT ) S [Ser] ) S [Ser]
rs3025039 VEGFA 6 43752536 3’-UTR — —
rs699947 VEGFA 6 43736389 Prom — —
rs833061 VEGFA 6 43737486 Prom — —
rs4604006 VEGFC 4 177608775 Intronic — —
rs7664413 VEGFC 4 177608707 Intronic — —
rs664393 FLT1 13 29071001 3’-UTR — —
rs7993418 FLT1 13 28883061 Syn; ESE TAC TAT ) Y [Tyr] ) Y [Tyr]
rs1870377 KDR 4 55972974 Missense CAA CAT ) Q [Gln] ) H [His]
rs2071559 KDR 4 55992366 Init. Transcription — —
rs2305948 KDR 4 55979558 Missense GTA ATA ) V [Val] ) I [Ile]
rs7667298 KDR 4 55991731 5’-UTR — —
rs307805 FLT4 5 180077487 Prom; TFBS — —
rs6877011 FLT4 5 180029471 3’-UTR — —
rs307822 FLT4 5 180028717 3’-UTR — —
Abbreviations: aa¼ aminoacid; Chr¼ chromosome; ESE¼ exon splicing enhancer; Prom¼promoter region; SNP¼ single-nucleotide polymorphism; Syn¼ synonymous substitution; TFBS¼
predicted transcription factor binding site; UTR¼untranslated region.
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Figure 1. Progression-free survival analysis of rs833061 (Po0.0001; the
lines ‘——’ and ‘——’ indicate TT and CCþCT, respectively).
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Figure 2. Progression-free survival analysis of rs2010963 (P¼ 0.0001;
the lines ‘——’, ‘——’ and ‘      ’ indicate CC, CG and GG,
respectively).
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Figure 3. Progression-free survival analysis of rs6877011 (P¼ 0.0075;
the lines ‘——’ and ‘——’ indicate CG and CC, respectively).
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Figure 4. Overall survival analysis of rs833061 (Po0.0001; the lines
‘——’ and ‘——’ indicate TT and CCþCT, respectively).
Table 2. Patient characteristics
Number of patients 84
Gender
Male 65 (77%)
Female 19 (33%)
Median age (range 47–84)
464 41 (49%)
o64 43 (51%)
Surgery
Yes 73 (87%)
No 11 (13%)
Histology
Clear cell 77 (92%)
Other 7 (8%)
ECOG
0 61 (73%)
1 14 (17%)
2 9 (10%)
Stage at diagnosis (AJCC Cancer Staging Manual, 2010)
I 4 (5%)
II 8 (9%)
III 43 (51%)
IV 29 (35%)
Best response
CR 2 (2%)
PR 10 (12%)
SD 24 (29%)
PD 48 (57%)
Abbreviations: AJCC¼American Joint Committee on Cancer; CR¼ complete response;
ECOG¼Eastern Cooperative Oncology Group performance score; PD¼progressive
disease; PR¼partial response; SD¼ stable disease.
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On multivariate analysis, rs833061 (HR¼ 0.71), rs2010963
(HR¼ 0.19) and rs68877011 (HR¼ 0.35) were significant in PFS.
rs833061 (HR¼ 0.69) and rs68877011 (HR¼ 0.39) were also
independent factors in OS.
Patients expressing all the favourable polymorphisms of
rs833061, rs2010963, rs699947 and rs68877011 seem to have
better overall response rate compared with those with unfavourable
ones (56 vs 12%).
DISCUSSION
Targeting the angiogenetic pathway resulted in a complete
revolution in the treatment and prognosis of mRCC. However,
in mRCC patients treated with anti-VEGF TKIs, PFS and OS may
widely vary from patient to patient, ranging from few weeks to
years, with no apparent explanation in most of the cases. These
observations may not be easily connected to the previous known
predictive and prognostic factors and risk categories (Pander et al,
2007).
A number of potential mechanisms of action involving both
stromal and cancer cells have been hypothesised for sunitinib.
Among these mechanisms, ‘vascular normalisation’ has the most
robust clinical evidence (Jain, 2005). Deprimo et al. (2007) recently
showed how TKIs targeting the RTKs (e.g., sunitinib) produce an
increase in VEGF levels and a decrease in soluble VEGFR-2
(sVEGFR-2) and sVEGFR-3 in cytokine-refractory patients with
mRCC. Interestingly, these changes in VEGF and sVEGFR were
observed during treatment with sunitinib, and levels tended to
return to near baseline after 2 weeks off treatment, indicating that
these effects were dependent on drug exposure. Furthermore,
significantly larger changes in VEGF, sVEGFR-2 and sVEGFR-3
levels were observed in patients exhibiting objective tumour
response compared with those exhibiting stable disease or disease
progression (Po0.05 for each analyte).
In our analysis, the CCþCT polymorphism of VEGF A
rs833061 proved statistically significant in PFS (Po0.0001) and OS
(Po0.0001) along with the AAþAC polymorphism of rs699947
(PFS, P¼ 0.0001; OS, Po0.0001). The CC polymorphism of
rs2010963 of VEGF A also showed significant correlation in PFS
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Figure 5. Overall survival analysis of rs6877011 (P¼0.0001; the lines
‘——’ and ‘——’ indicate CG and CC, respectively).
Table 3. Polymorphism results in univariate and multivariate analyses
Univariate Multivariate
Polymorphism Genotype No. of patients PFS OS PFS OS
VEGF A
rs833061 CCþCT 60
TT 24
Po0.0001 Po0.0001 P¼ 0.0197 P¼0.0011
HR¼0.71 HR¼ 0.69
rs2010963 CC 8
CG 39
GG 37
P¼ 0.0001 P¼0.0045 P¼ 0.0201 P¼0.5932
HR¼0.19 HR¼ 0.24
rs699947 AAþAC 60
CC 24
P¼ 0.0001 Po0.0001 P¼ 0.9801 P¼0.5856
HR¼0.69 HR¼ 0.65
VEGFR3
rs6877011 CC 71
CG 13
GG 0
P¼ 0.0075 P¼0.0001 Po0.0001 Po0.0001
HR¼0.35 HR¼ 0.39
Abbreviations: HR¼ hazard ratio; OS¼ overall survival; PFS¼progression-free survival; VEGF¼ vascular endothelial growth factor; VEGFR3¼VEGF receptor 3.
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(P¼ 0.0001) and OS (P¼ 0.0045). rs833061 is located in the
promoter region of the VEGF A gene on chromosome 6, similar to
rs699947, whereas rs2010963 is located in the terminal 50-UTR
region of the VEGF A gene. We can hypothesise that different
SNPs in different regions of the VEGF gene may influence
circulating levels of VEGF and thus response to anti-VEGF
therapies.
These findings and hypothesis could explain how a certain
constitutive variation in VEGF and VEGFR levels could exert a
significant difference in tumour outcome during antiangiogenetic
treatment. Candidate gene studies exploring associations between
VEGF polymorphisms and circulating VEGF levels have yielded
controversial results. Eight studies have found significant associa-
tions with candidate polymorphisms (rs699947, rs1570360,
rs833061, rs2010963, rs3025039, and 2549 18 bp I/D) in the
promoter, 50- and 30-UTRs of the VEGF gene (Renner et al, 2000;
Awata et al, 2002; Krippl et al, 2003; Ferrante et al, 2006; Zhai et al,
2007; Kamoun et al, 2008; Petrovic et al, 2008). However, several
other studies did not identify any association with these and other
VEGF SNPs. Using a hypothesis-free genome-wide approach,
Debette et al (2011) found associations with 140 SNPs. Of these, 68
SNPs are located on chromosome 6, B150 kb downstream from
the 30 end of the VEGF gene, far from previously tested candidate
SNPs. However, the real effect of SNPs in circulating or tumour
tissue VEGF levels needs further studies in order to definitively
associate a specific SNP to a specific effect on the corresponding
growth factor or receptor.
In our population, we also found a statistical significance in PFS
(P¼ 0.0075) and OS (P¼ 0.0001) in the CC polymorphism of
rs6877011 of VEGFR 3.
Angiogenic sprouting involves specification of subpopulations
of endothelial cells into tip cells that respond to VEGF guidance
cues, and stalk cells that follow the tip cells and proliferate to form
the vascular network (Gunningham et al, 2001). Recent evidence
indicates that VEGF induces the membrane-bound Notch ligand
delta-like 4 (Dll4) in the tip cells, which leads to the induction of
the stalk cell phenotype in adjacent endothelial cells through
activation of Notch-1 (Laakkonen et al, 2007).
In conclusion, our data show that by analysing polymorphisms
of the VEGF and VEGFR genes, we could be able to select proper
patients to be treated with sunitinib to improve treatment outcome.
Further prospective studies are warranted to confirm our findings.
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